Pinyol, Roser
Montal, Robert
Bassaganyas, Laia
Sia, Daniela
Takayama, Tadatoshi
Chau, Gar-Yang
Mazzaferro, Vincenzo
Roayaie, Sasan
Lee, Han Chu
Kokudo, Norihiro http://orcid.org/0000-0001-7279-9702
Zhang, Zhongyang
Torrecilla, Sara
Moeini, Agrin
Rodriguez-Carunchio, Leonardo
Gane, Edward
Verslype, Chris
Croitoru, Adina Emilia
Cillo, Umberto
de la Mata, Manuel
Lupo, Luigi
Strasser, Simone
Park, Joong-Won
Camps, Jordi
Solé, Manel
Thung, Swan N
Villanueva, Augusto
Pena, Carol
Meinhardt, Gerold
Bruix, Jordi http://orcid.org/0000-0002-9826-0753
Llovet, Josep M
Clinical trials referenced in this document:
Documents that mention this clinical trial
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
https://doi.org/10.1136/gutjnl-2018-316408
Documents that mention this clinical trial
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
https://doi.org/10.1136/gutjnl-2018-316408
Funding for this research was provided by:
Agència de Gestió d’Ajuts Universitaris i de Recerca
Generalitat de Catalunya
National Cancer Institute
Association for International Cancer Research
Spanish Health Ministry - Plan estratégico Nacional contra la Hepatitis C
Bayer HealthCare
American Association for the Study of Liver Diseases
Fundación Científica Asociación Española Contra el Cáncer
Tisch Cancer Institute
Horizon 2020 Framework Programme
Spanish National Health Institute
Samuel Waxman Cancer Research Foundation
Spanish Ministry of Economy and Competitiveness
U.S. Department of Defense
Instituto de Salud Carlos III
Onyx Pharmaceuticals